Abivax SA (ABVX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.157x

Based on the latest financial reports, Abivax SA (ABVX) has a cash flow conversion efficiency ratio of -0.157x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-71.28 Million ≈ $-83.34 Million USD) by net assets (€455.20 Million ≈ $532.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Abivax SA to measure how many days the company can operate on defensive assets alone.

Abivax SA - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Abivax SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Abivax SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Abivax SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Laurus Labs Limited NSE:LAURUSLABS	0.222x
Evonik Industries AG F:EVK	0.075x
BlueFocus Communication Group SHE:300058	0.064x
Trade Desk Inc NASDAQ:TTD	0.125x
FactSet Research Systems Inc NYSE:FDS	0.099x
Full Truck Alliance Co Ltd ADR NYSE:YMM	0.038x
Simpson Manufacturing Company Inc NYSE:SSD	0.017x
Columbia Banking System Inc NASDAQ:COLB	0.036x

Annual Cash Flow Conversion Efficiency for Abivax SA (2013–2025)

The table below shows the annual cash flow conversion efficiency of Abivax SA from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Abivax SA (ABVX) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€455.20 Million ≈ $532.18 Million	€-162.09 Million ≈ $-189.50 Million	-0.356x	+90.62%
2024-12-31	€40.58 Million ≈ $47.45 Million	€-154.07 Million ≈ $-180.13 Million	-3.796x	-666.11%
2023-12-31	€196.01 Million ≈ $229.16 Million	€-97.13 Million ≈ $-113.56 Million	-0.496x	+98.58%
2022-12-31	€1.88 Million ≈ $2.20 Million	€-65.58 Million ≈ $-76.67 Million	-34.845x	-2096.03%
2021-12-31	€28.77 Million ≈ $33.64 Million	€-45.66 Million ≈ $-53.38 Million	-1.587x	+75.14%
2020-12-31	€4.67 Million ≈ $5.46 Million	€-29.82 Million ≈ $-34.87 Million	-6.382x	-173.67%
2019-12-31	€11.78 Million ≈ $13.77 Million	€-27.47 Million ≈ $-32.12 Million	-2.332x	-453.39%
2018-12-31	€34.65 Million ≈ $40.51 Million	€-14.60 Million ≈ $-17.07 Million	-0.421x	-140.30%
2017-12-31	€48.18 Million ≈ $56.33 Million	€-8.45 Million ≈ $-9.88 Million	-0.175x	+36.28%
2016-12-31	€56.72 Million ≈ $66.31 Million	€-15.61 Million ≈ $-18.25 Million	-0.275x	-32.46%
2015-12-31	€71.74 Million ≈ $83.87 Million	€-14.90 Million ≈ $-17.42 Million	-0.208x	-113.32%
2014-12-31	€33.94 Million ≈ $39.67 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	-0.25%
2013-12-31	€34.02 Million ≈ $39.77 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	--

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$7.99 Billion

€6.83 Billion EUR

Market Cap Rank

#2669 Global

#55 in France

Share Price

€86.20

Change (1 day)

-2.38%

52-Week Range

€5.18 - €122.40

All Time High

€122.40